Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome

Authors:
Daniela Weiskopf, Katharina S. Schmitz, Matthijs P. Raadsen, Alba Grifoni, Nisreen M.A. Okba, Henrik Endeman, Johannes P.C. van den Akker, Richard Molenkamp, Marion P.G. Koopmans, Eric C.M. van Gorp, Bart L. Haagmans, Rik L. de Swart, Alessandro Sette & Rory D. de Vries
In:
Source: Science
Publication Date: (2020)
Issue: 5: 48
Research Area:
Immunotherapy / Hematology
Respiratory Research
Cells used in publication:
T cell, human peripheral blood unstim.
Species: human
Tissue Origin: blood
T cell, human stim.
Species: human
Tissue Origin: blood
Experiment

Upon use, PBMC were thawed in IMDM (Lonza, Belgium) supplemented with 10% FBS, 100 IU of penicillin/ml, 100 µg of streptomycin/ml (Lonza, Belgium) and 2 mM L-glutamine (Lonza, Belgium) (I10F medium).

PBMC were plated in 96-wells U bottom plates at 1 x 106 PBMC per well in RPMI1640 (Lonza, Belgium) supplemented with 10% human

serum, 100 IU of penicillin/ml, 100 µg of streptomycin/ml (Lonza, Belgium) and 2 mM L-glutamine (Lonza, Belgium) (R10H medium) and subsequently stimulated with the

described CD4 and CD8 SARS-CoV-2 MPs at 1µg/ml.

Abstract

COVID-19 is associated with lymphopenia and ‘cytokine storm’, but no information is available on specific cellular immune responses to SARS-CoV-2. Here, we

characterized SARS-CoV-2-specific CD4+ and CD8+ T-cells in patients with acute respiratory distress syndrome. The spike protein (S) proved a potent T-cell antigen

and specific T-cells predominantly produced Th1 cytokines. These novel data are important in vaccine design and will facilitate evaluation of vaccine candidate

immunogenicity.